MedPath

Establishment of Natural History of Scorpion Envenomation

Completed
Conditions
Scorpion Sting Envenomation
Interventions
Other: None, this is an observational study
Registration Number
NCT00696683
Lead Sponsor
Instituto Bioclon S.A. de C.V.
Brief Summary

This retrospective study was conducted to collect data from approximately 100 patients from 6 months to 18 years of age who were stung by a scorpion but were not treated with antivenom. The study consisted of a review of hospital records of patients who were admitted for intensive care management of scorpion envenomation, at the only two hospitals in North America known to admit children routinely for scorpion sting management without antivenom. The standard of care consisted of symptomatic and supportive care, including airway maintenance, fluid and electrolyte support and, if necessary, sedation.

Detailed Description

The study objective was to document the clinical syndrome of scorpion envenomation in the absence of antivenom treatment in pediatric patients. This was done to establish historical control data on the time from sting to the time of resolution of signs of envenomation. These historical control data are intended to be used for comparison with Alacramyn treated patients in two prospective studies being conducted in Mexico and the U.S.for which a control population could not otherwise be established.

The total duration of clinically important systemic signs of envenomation was determined based upon overall investigator assessment of the last signs of any respiratory compromise, any pathological agitation or other indicator of continuing illness (e.g., continuing need for sedative administration).

To facilitate comparison of these historical data with prospective open label trials, periodic assessments of the overall presence or absence of clinically important signs was performed. Periodic assessments were also performed for each individual component indicator of respiratory compromise and of pathological agitation, when available.

A research nurse reviewed hospital discharge diagnoses for all pediatric charts coded for "scorpion sting". For these cases demographic, diagnostic, and therapeutic data were entered on the case report form (CRF) as well as data necessary to assess compliance with study inclusion and exclusion criteria.

A physician subinvestigator reviewed the research nurse's findings for the key outcome indicators, which consisted of clinically important systemic signs of scorpion envenomation and adjunctive sedation treatment (dose and timing of dose) when medical judgment was required.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
97
Inclusion Criteria
  • Males and females 6 months to 18 years of age
  • Presenting for emergency treatment with clinically important systemic signs of scorpion sting envenomation
Exclusion Criteria
  • Use of any antivenom within the last month or concomitantly
  • Signs and symptoms confined to local sting site
  • Concurrent medical condition involving a baseline neurologic status mimicking envenomation (chorea, tardive dyskinesia, uncontrolled epilepsy)
  • Incomplete or unavailable medical record

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
ANone, this is an observational studyPatients from the identified scorpion envenomation cases, who met inclusion/exclusion criteria.
Primary Outcome Measures
NameTimeMethod
Assessment of overall duration of clinically important signs of scorpion envenomation (Clinically important signs of envenomation were divided into those indicative of respiratory distress and those comprising pathological agitation)4 hours or discharge
Secondary Outcome Measures
NameTimeMethod
To characterize treatment in the absence of antivenom (total dose, maximum rate per hour and duration of use of midazolam)4 hours or discharge

Trial Locations

Locations (1)

The University of Arizona Health Science Center & Tucson Medical Center

🇺🇸

Tucson, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath